San Diego, California, October 24, 2017 – Forge Therapeutics, Inc. (Forge) announced today that the company will be participating in several scientific and industry events over the next quarter. Details of the events are listed below.
Event: San Diego innovation showcase
Date: October 26, 2017
Location: Hilton La Jolla Torrey Pines, La Jolla, CA
Presentation Title: Forging New Chemistry Platforms for Generating Novel Medicines
Event: Keystone symposia on antimicrobials and resistance
Date: October 29-November 2, 2017
Location: Eldorado Hotel & Spa, Santa Fe, New Mexico
Poster and Oral Presentation Title: Activity of non-hydroxamate lpxc inhibitors against Acinetobacter baumannii
Event: New venture models for biotech
Date: November 2, 2017
Location: The Alexandria at Torrey Pines, San Diego, CA
Panel Title: Biotech Breakouts: Emerging Luminaries of San Diego
Event: Barda’s industry day
Date: November 7-8, 2017
Location: Washington D.C.
Panel Title: Powered by CARB-X, How CARB-X is Accelerating Antibacterial Innovation
Event: Superbugs & superdrugs
Date: November 13-14, 2017
Location: Renaissance Woodbridge Hotel, Iselin, New Jersey
Presentation Title: Forging Ahead with a New Class of Antibiotics
About Forge Therapeutics
At Forge Therapeutics, we are developing medicines targeting metal-dependent enzymes found in nature. Over 30% of known enzymes are metalloenzymes covering all major enzymes classes: oxidoreductases, transferases, hydrolases, lyases, isomerases, and ligases. Metal ions, including magnesium, zinc, iron, manganese, calcium, cobalt, and copper are the essential ingredient in these metalloenzymes. At Forge, we are the blacksmiths of modern medicine, providing the tools to address any metalloenzyme challenge.
Forge’s lead effort is focused on LpxC, a zinc metalloenzyme found only in Gram-negative bacteria and which is essential for bacteria to grow. Forge has a strategic alliance with leading drug discovery alliance and development partnership company Evotec AG and has been awarded multiple government awards including CARB-X. In addition, Forge has amassed a rich intellectual property estate on metalloprotein inhibitors to protect its BLACKSMITH platform and pipeline including technology licensed from UCSD. For further information, please visit the company’s website www.ForgeTherapeutics.com and follow us on Twitter @ForgeThera.
Forge Company Contact:
Forge Media Contact: